Clinical Trials · NCT06898060

To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture

Name: To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

Not Yet RecruitingPhase 3Teriparatide Abaloparatide

Phase: Phase 3
Recruitment status: Not Yet Recruiting
Sponsor: Qilu Pharmaceutical Co., Ltd.
Enrollment: 282
Start date: Jun 2025
Locations: See registry
Primary endpoint: Percent Change in Bone Mineral Density (BMD) of Lumbar Spine From Baseline to 52 Week

View Teriparatide compound reference